---
document_datetime: 2023-09-21 20:00:33
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps/osseor-epar-procedural-steps-taken-authorisation_en.pdf
document_name: osseor-epar-procedural-steps-taken-authorisation_en.pdf
version: success
processing_time: 0.4221365
conversion_datetime: 2025-12-22 20:39:04.54325
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## BACKGROUND INFORMATION ON THE PROCEDURE

## 1 Submission of the dossier

The  applicant  Les  Laboratoires  Servier  submitted  on  25  June  2003  an  application  for  Marketing Authorisation to the European Agency for the Evaluation of Medicinal Products (EMEA) for Osseor, through the centralised procedure. After agreement by the CPMP on 19 March 2003, this medicinal product has been referred to Part B of the Annex to Council Regulation No (EEC) 2309/93 of 22 July 1993 as amended.

The Rapporteur and Co-Rapporteur appointed by the CHMP were:

- The  PhWP  report  on  the  pharmacovigilance  plan  for  Osseor  was  circulated  to  all  CPMP members on 22 June 2004

Rapporteur: Dr. Per Nilsson Co-Rapporteur: Prof. Josef Suko Licensing status : The product was not licensed in any country at the time of submission of the application. 2 Steps taken for the assessment of the product · The procedure started on 21 July 2003. · The Rapporteur's first Assessment Report was circulated to all CPMP  members  on 1  October  2003  .  The  Co-Rapporteur's  first  Assessment  Report  was  circulated  to  all  CPMP members on 6 October 2003 · During  the  meeting  on  20  November  2003,  the  CPMP  agreed  on  the  consolidated  List  of Questions to be sent to the applicant. The final consolidated List of Questions was sent to the applicant on 20 November 2003 . · The  applicant  submitted  the  responses  to  the  CPMP  consolidated  List  of  Questions  on 12 February 2004. · The Rapporteurs circulated the Joint Assessment Report on the applicant's responses to the List of Questions to all CPMP members on 19 March 2004 · During the CPMP meeting on 22 April 2004, the CPMP agreed on a list of outstanding issues to be addressed in writing by the applicant · The applicant submitted written answers to the list of outstanding issues on 14 May 2004. · The  Rapporteurs  circulated  a  revised  Joint  Assessment  Report  on  the  applicant's  written responses to the list of outstanding issues on 28 May 2004 · Following  a  request  by  the  Rapporteurs  the  PhWP  reviewed  the  pharmacovigilance  plan  for Osseor during the meeting on 22 June 2004. Medicinal product no longer authorised

- The  applicant submitted  a revised Pharmacovigilance  plan  on  22  June  2004  that  was subsequently discussed and agreed by CHMP
- During the meeting on 22-23 June 2004, the CHMP, in the light of the overall data submitted and  the  scientific  discussion  within  the  Committee,  issued  a  positive  opinion  for  granting  a Marketing  Authorisation  to  Osseor  on  23  June  2004.  The  applicant  provided  the  letter  of undertaking on the follow-up measures to be fulfilled post-authorisation on 21 June 2004.
- The CHMP opinions were forwarded, in all official languages of the European Union, to the European Commission, which adopted the corresponding decisions on 21 September 2004.

1/1